ライフサイエンスコーパス: CYP27A1

1 CYP27A1 exhibited only three Lys residues, Lys(134), Lys

2 CYP27A1 is considered a potential therapeutic target in

3 CYP27A1 may participate in the removal of harmful autoxi

4 CYP27A1 was shown to mediate the reduction of cholestero

5 Cytochrome P450 27A1 (CYP27A1 or sterol 27-hydroxylase) is a ubiquitous, multi

6 Cytochrome P450 27A1 (CYP27A1) is a ubiquitous enzyme that hydroxylates choles

7 Mitochondrial cytochrome P450 27A1 (CYP27A1) is a ubiquitous multifunctional sterol C27-hydr

8 Cytochrome P450 27A1 (CYP27A1) is a ubiquitously expressed mitochondrial stero

9 bufagenin levels doubled, and adrenocortical CYP27A1 mRNA and protein increased 1.6-fold and 2.0-fold

10 T110, M301C, V367, I481, and V482) affected CYP27A1 binding and enzyme activity in a substrate-depen

11 and some astrocytes in the normal brain, and CYP27A1 is present in oligodendrocytes.

12 Expression of VDR, CYP2R1, and CYP27A1 was evaluated via immunohistochemistry in hepato

13 with NASH and CHC expressed VDR, CYP2R1, and CYP27A1.

14 nocytochemical studies show that CYP46A1 and CYP27A1 are expressed in neurons and some astrocytes in

15 Both CYP27A1 and CYP46A1 are expressed in primate retina indi

16 27HC), a derivative of cholesterol formed by CYP27A1, can mobilize cholesterol from the lysosomes to

17 ble for production of 27HC from cholesterol, CYP27A1, is expressed primarily in the liver and in macr

18 Complete CYP27A1 deficiency owing to genetic mutations is detrime

19 In humans, complete CYP27A1 deficiency leads to cerebrotendinous xanthomatos

20 ry of cholesterol to mitochondria containing CYP27A1.

21 Additionally, CYP7A1, CYP11A1, CYP27A1, and CYP46A1 are parts of a broader cholesterol

22 dR) and tightly associated (CYP7B1, CYP11A1, CYP27A1, and CYP46A1) membrane proteins were quantified.

23 cytochrome P450 (CYP) isoform 7A1 (CYP7A1), CYP27A1, CYP8B1, uridine 5'-diphospho-glucuronosyltransf

24 cally downregulated genes identified encodes CYP27A1, an enzyme involved in regulating cellular chole

25 acid pathway, which is controlled by enzyme CYP27A1.

26 HC), synthesized by the mitochondrial enzyme CYP27A1, was identified as one of the major de novo adip

27 es encoding the bile acid metabolism enzymes CYP27A1 and CYP3A11 as well as canalicular bile salt pum

28 cholesterol 25-hydroperoxide to the enzymes CYP27A1 and CYP11A1 induced well-defined spectral change

29 d at the protein level by immunostaining for CYP27A1 in annotated tissue microarrays.

30 s as immune modulators and a direct role for CYP27A1 in generating these RORgammat agonist ligands, w

31 n cholestanol in the cerebellum arising from CYP27A1 deficiency.

32 plain in part why humans who lack functional CYP27A1 do not display a corresponding increase in CYP3A

33 isms (SNPs) of five vitamin D-related genes (CYP27A1, CYP2R1, CYP27B1, GC and VDR) were genotyped in

34 brosis stage was associated with low hepatic CYP27A1 expression, whereas portal inflammation was sign

35 related neurodegenerative diseases; however, CYP27A1 inhibition should be </=50%.

36 Hydrophobic bile acids suppress human CYP27A1 gene reporter activity when assayed in human hep

37 Results suggest that human CYP27A1 gene transcription is suppressed by bile acids a

38 a region downstream of nt -147 of the human CYP27A1 gene, within which a binding site for a liver-sp

39 Mitochondrial sterol 27-hydroxylase (CYP27A1) catalyses sterol side-chain oxidation of bile a

40 Sterol 27-hydroxylase (CYP27A1) is required for bile acid synthesis by both the

41 se (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1).

42 Mice deficient in CYP27A1, a key enzyme in generating these oxysterols, sh

43 st-translational modifications identified in CYP27A1 exemplify a general mechanism whereby oxidative

44 a lipid storage disorder due to mutations in CYP27A1, typically characterized by DN damage.

45 (dasatinib) elicited a spectral response in CYP27A1 and had Ki values for cholesterol 27-hydroxylati

46 xi-hydroperoxides induced spectral shifts in CYP27A1 and CYP11A1 but glycol metabolites were detected

47 Bile acids also inhibit CYP27A1 reporter activity in human embryonic kidney 293

48 Of them, 14 drugs inhibited CYP27A1 by >/=75% and were evaluated for in vitro bindin

49 c analysis revealed homozygosity for a known CYP27A1 mutation (c.1263+1G --> A) in the 3 symptomatic

50 ation of an internal standard, (15)N-labeled CYP27A1 modified with iso[4]LGE(2), for the subsequent a

51 ensive ophthalmic evaluation of mice lacking CYP27A1.

52 Importantly, lower CYP27A1 transcript levels were associated with shorter d

53 a biochemical activity similar to mammalian CYP27A1 catalyzing addition of a terminal acid to the si

54 pathway, which is initiated by mitochondrial CYP27A1.

55 These data demonstrate that modified CYP27A1 is present in the retina.

56 ere diagnosed (mutations in PAH, CBS, MTHFR, CYP27A1, and HIBCH), and in 1 family, 2 disease-causing

57 of CYP46A1 and high cerebellar abundance of CYP27A1, the lack of which probably selectively increase

58 The present work assessed druggability of CYP27A1 as a potential antibreast cancer target.

59 renocortical cells reduced the expression of CYP27A1 mRNA by 70%, reduced total bile acids 2-fold, an

60 However, expression of CYP27A1, the rate-determining enzyme in the alternate pa

61 Inhibition of CYP27A1 activity or knockdown and deletion of the Cyp27a

62 have unanticipated off-target inhibition of CYP27A1, and we propose strategies for their identificat

63 Ablation or inhibition of CYP27A1, the enzyme responsible for the rate-limiting st

64 Loss of CYP27A1 in prostate cancer was confirmed at the protein

65 We found that the loss of CYP27A1 led to dysregulation of retinal cholesterol home

66 Our results enhance the potential of CYP27A1 as an antibreast cancer target, could be of impo

67 ycholesterol (27HC), an enzymatic product of CYP27A1, reduced cellular cholesterol content in prostat

68 Restoration of CYP27A1 expression in cells where its gene was silenced

69 poietic stem/progenitor cells as a result of CYP27A1, a cholesterol hydroxylase.

70 opic eczema was associated with rs4674343 of CYP27A1 (odds ratio 0.66, 95% confidence interval 0.53-0

71 rmaceuticals were tested for their effect on CYP27A1-mediated cholesterol 27-hydroxylation by in vitr

72 A vitamin D-related SNP rs4674343 on CYP27A1 was found to be protective against atopic eczema

73 Cytochrome P450 27A1 (P450 27A1 or CYP27A1) is an important enzyme that participates in dif

74 Mutations in CYP7B1 or CYP27A1, which encode enzymes involved in cholestenoic a

75 rsion to 27HC by the cytochrome P450 oxidase CYP27A1 and were attenuated by treatment with CYP27A1 in

76 Cytochrome P450 CYP27A1 is the only enzyme in humans converting choleste

77 th sterol 27-hydroxylase, a cytochrome P450 (CYP27A1); however, the identity of the microsomal enzyme

78 shed for the retina, where cytochromes P450 (CYP27A1 and CYP46A1) are the major cholesterol-metaboliz

79 l as the scaffold with potential for partial CYP27A1 inhibition in humans.

80 Thus, pharmacologic CYP27A1 inhibition is possible in the whole body and ind

81 nerative storage disease caused by recessive CYP27A1 mutations and is characterized by abnormal depos

82 vitro for inhibition of purified recombinant CYP27A1 and binding to the enzyme active site.

83 Treatment of purified recombinant CYP27A1 with authentic iso[4]levuglandin E(2) (iso[4]LGE

84 In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade.

85 HNF4alpha strongly stimulates CYP27A1 gene transcription and mutation of its binding s

86 Six strong CYP27A1 inhibitors/binders were identified.

87 e is known about its metabolism, except that CYP27A1 might metabolize cholestanol.

88 We confirmed our previous finding that CYP27A1 is a druggable enzyme and found additional drugs

89 Our findings suggest that CYP27A1 is a critical cellular cholesterol sensor in pro

90 Mutation of Arg-418, conserved in the CYP27A1 family, to serine also decreased the affinity fo

91 w that post-transcriptional silencing of the CYP27A1 gene in human trophoblast and rat adrenocortical

92 chondrial cytochrome P450c27 (product of the CYP27A1 gene) is found to have significantly higher affi

93 Distinct binding of the CYP27A1 substrates may provide insight into why phenotyp

94 prostate cells and that dysregulation of the CYP27A1/27HC axis contributes significantly to prostate

95 ity toward the CYP24 enzyme in comparison to CYP27A1 (IC(50) > 1000 nM) and CYP27B (IC(50) = 554 nM).

96 trocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not appar

97 ed in the bypass of peripheral TOMs, whereas CYP27A1 interacted only with Hsp70 and was not able to b

98 It also is unclear why CYP27A1 deficiency results in preferential cholestanol a

99 We quantified sterols along with CYP27A1 and CYP46A1 in mouse models (Cyp27a1(-/-), Cyp46

100 ous xanthomatosis, a disease associated with CYP27A1 deficiency, are so diverse.

101 e-3alpha,7alpha,12alpha-triol, interact with CYP27A1.

102 YP27A1 and were attenuated by treatment with CYP27A1 inhibitors.